Old Dominion University

ODU Digital Commons
Medical Diagnostics & Translational Sciences
Faculty Publications

Medical Diagnostics and Translational Sciences

2015

Bioactive Lipid Coating of Bone Allografts Direct
Engraftment and Fate Determination of Bone
Marrow-Derived Cells in Rat GFP Chimeras
Anusuya Das
Claire E. Segar
Yihsuan Chu
Tiffany W. Wang
Yon Lin
See next page for additional authors

Follow this and additional works at: https://digitalcommons.odu.edu/medicaldiagnostics_fac_pubs
Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons,
Biomedical Engineering and Bioengineering Commons, and the Orthopedics Commons
Repository Citation
Das, Anusuya; Segar, Claire E.; Chu, Yihsuan; Wang, Tiffany W.; Lin, Yon; Yang, Chunxi; and Ogle, Roy C., "Bioactive Lipid Coating
of Bone Allografts Direct Engraftment and Fate Determination of Bone Marrow-Derived Cells in Rat GFP Chimeras" (2015). Medical
Diagnostics & Translational Sciences Faculty Publications. 26.
https://digitalcommons.odu.edu/medicaldiagnostics_fac_pubs/26

Original Publication Citation
Das, A., Segar, C. E., Chu, Y. H., Wang, T. W., Lin, Y., Yang, C. X., . . . Botchwey, E. A. (2015). Bioactive lipid coating of bone allografts
directs engraftment and fate determination of bone marrow-derived cells in rat GFP chimeras. Biomaterials, 64, 98-107. doi:10.1016/
j.biomaterials.2015.06.019

This Article is brought to you for free and open access by the Medical Diagnostics and Translational Sciences at ODU Digital Commons. It has been
accepted for inclusion in Medical Diagnostics & Translational Sciences Faculty Publications by an authorized administrator of ODU Digital Commons.
For more information, please contact digitalcommons@odu.edu.

Authors

Anusuya Das, Claire E. Segar, Yihsuan Chu, Tiffany W. Wang, Yon Lin, Chunxi Yang, and Roy C. Ogle

This article is available at ODU Digital Commons: https://digitalcommons.odu.edu/medicaldiagnostics_fac_pubs/26

~
1
IC~I
HHS Public Access
Author manuscript

Author Manuscript

Biomaterials. Author manuscript; available in PMC 2016 September 01.

Published in final edited form as:
Biomaterials. 2015 September ; 64: 98–107. doi:10.1016/j.biomaterials.2015.06.019.

Bioactive lipid coating of bone allografts directs engraftment
and fate determination of bone marrow-derived cells in rat GFP
chimeras
Anusuya Dasa,b,1, Claire E. Segarc,1, Yihsuan Chuc, Tiffany W. Wangc, Yong Linb, Chunxi
Yangd, Xeujun Due, Roy C. Oglef, Quanjun Cuia, and Edward A. Botchweyc,*

Author Manuscript

aDepartment

of Orthopaedic Surgery, University of Virginia, Charlottesville, VA, USA

bDepartment

of Biomedical Engineering, University of Virginia, Charlottesville, VA, USA

cDepartment

of Biomedical Engineering, Georgia Institute of Technology and Emory University,
Atlanta, GA, USA
dDepartment

of Orthopaedic Surgery, Tenth People’s Hospital of Tongji University, Shanghai
200072, China

eDepartment

of Orthopaedic Surgery, The First Affiliated Hospital of Xinxiang Medical University,
Xinxiang 453100, China
fSchool

of Medical Diagnostic and Translational Sciences, Old Dominion University, Norfolk, VA,

USA

Author Manuscript

Abstract

Author Manuscript

Bone grafting procedures are performed to treat wounds incurred during wartime trauma,
accidents, and tumor resections. Endogenous mechanisms of repair are often insufficient to ensure
integration between host and donor bone and subsequent restoration of function. We investigated
the role that bone marrow-derived cells play in bone regeneration and sought to increase their
contributions by functionalizing bone allografts with bioactive lipid coatings. Polymer-coated
allografts were used to locally deliver the immunomodulatory small molecule FTY720 in tibial
defects created in rat bone marrow chimeras containing genetically-labeled bone marrow for
monitoring cell origin and fate. Donor bone marrow contributed significantly to both myeloid and
osteogenic cells in remodeling tissue surrounding allografts. FTY720 coatings altered the
phenotype of immune cells two weeks post-injury, which was associated with increased
vascularization and bone formation surrounding allografts. Consequently, degradable polymer
coating strategies that deliver small molecule growth factors such as FTY720 represent a novel
therapeutic strategy for harnessing endogenous bone marrow-derived progenitors and enhancing
healing in load-bearing bone defects.
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1. Introduction

Author Manuscript

Bone grafting is the second most common transplant operation after blood, with more than
500,000 bone grafting procedures in the United States annually and 2.2 million worldwide
[1]. Autograft usage is the gold standard for bone graft transplant due to its osteoinductive,
osteoconductive, and osteogenic properties [1–3]. However, autografting procedures may
lead to donor site complications in as many as 30% of patients and is often insufficient for
the treatment of massive bone loss such as that suffered during acute trauma and limb
salvage surgeries [3]. Allograft, or transplantation tissue harvested from a donor, is a viable
alternative to autograft and constitutes approximately one-third of all bone grafting
procedures performed in the United States [4]. While use of allografts eliminates the risk of
donor site morbidity, the risk of disease transmission from donor to patient necessitates the
need for extensive sterilization procedures that often minimize the osteoinductive and
osteogenic properties [3,4]. New strategies are needed to restore the lost therapeutic
properties of allografts to enable adequate integration with host bone and ensure restoration
of function.
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Endogenous cell populations represent a powerful and adaptable tool for improving the host
regenerative response after injury. Typical stages of bone healing include hematoma
formation at the fracture site, which leads to the infiltration of myeloid cells (primarily
neutrophils and monocytes) and the development of granulation tissue and new blood
vessels. Mesenchymal stem cells (MSCs) then migrate into the fracture site and begin
proliferating and differentiating into osteoblasts, chondrocytes, and fibroblasts that
eventually form a callus, ending with growth and remodeling of new bone [5]. Both myeloid
cells and mesenchymal cells can migrate from adjacent bone marrow and may infiltrate the
injury site from the blood in response to damaged endothelium and chemotactic cues. The
precise origin of MSCs and osteoblastic progenitor cells is not well understood despite
evidence that the blood, bone marrow, and adjacent tissue compartments may serve as
sources for mesenchymal cells [6]. MSCs serve as both direct and indirect contributors to
bone repair, directly differentiating into bone-forming cells and secreting
immunomodulatory factors that condition the injury microenvironment and participate in
reciprocal signaling with inflammatory cells [5]. Bone marrow-derived monocytes and
macrophages appear to play multi-faced roles in bone repair, regulating the acute
inflammatory response [7], contributing to the pool of myeloid-derived pre-osteoclasts [8],
and secreting factors that enable intramembranous ossification [9]. Osteal macrophages or
“osteomacs” are present in bone both homeo-statically and after injury and their depletion
completely eliminates the endosteal bone-forming osteoblast lining [10]. Moreover, the
desired phenotype of macrophages, whether pro-inflammatory “M1-like” or antiinflammatory “M2-like”, and the dynamics of their persistence in tissue after initial injury is
likely important, but not well understood.
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Regulating the relative contributions of endogenous therapeutic cells from distinct
compartments is likely critical to improving biomaterial-based therapies for promoting bone
regeneration. Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid growth factor that
plays physiological roles in immune cell trafficking [11,12], vascular network formation and
maturation [13,14], and osteogenic activities [15] and thus represents a likely therapeutic
target for regulating cell populations within the injury niche. FTY720, a structural analog of
sphingosine that activates signaling through four of the five known S1P receptors, has
previously been shown to improve endothelial integrity, promote osteogenesis, and inhibit
osteoclastogenesis [15–17]. Previous studies in our lab have demonstrated that biomaterialbased delivery of FTY720 induces angiocrine signaling within the endothelium to recruit
pro-regenerative cell types such as anti-inflammatory monocytes and pro-angiogenic M2
macrophages [18,19] that facilitate neovascularization and bone formation [20–22].
Encapsulation within poly(lactic-co-glycolic acid) (PLGA) enables sustained release and
signaling of FTY720 for at least 3 days in vivo and generates gradients that spatially localize
pro-regenerative responses to peri-implant tissue [12]. S1P signaling also regulates
reciprocal signaling between osteoblasts and osteoclasts [15], as well as induces plateletderived growth factor (PDGF)-BB secretion by monocytic pre-osteoclasts that promotes
coupling between angiogenesis and osteogenesis [8].

Author Manuscript

Given that successful bone requires precise coordination between multiple cell types, we
designed a series of studies to assess the ability of FTY720-coated allografts to direct the in
situ fate of marrow-derived cells in a rat critical-sized segmental tibial defect model. We
used a rat bone marrow chimera model that is derived from transplantation of bone marrow
cells harvested from transgenic eGFP-expressing animals into lethally irradiated wild type
(WT) animals. The use of rat bone marrow chimeras is particularly advantageous in that
GFP+ hematopoietic cells are stably retained in vivo and easily monitored using
fluorescence microscopy without the need for histochemical staining or in situ hybridization
[23]. Consequently, the eGFP rat chimera has been used for investigating the
multipotentiality and migration of bone marrow-derived cells in a number of different
models, including tendon repair, bladder regeneration, and adipose tissue [23–25]. However,
bone repair, in which the rat model offers a significantly better representation of human
physiology than parallel mouse models, has not been investigated in rat bone marrow
chimeras. Consequently, we investigated the relative contributions of the blood and bone
marrow to bone repair using transgenic-based labeling of hematopoietic cells and assessed
the fate of cells infiltrating in response to volumetric bone loss.

2. Materials and methods
Author Manuscript

2.1. Chimera creation
33 8-week old female eGFP−/− Sprague Dawley (SD) rats received transgenic bone marrow
transplantation from 11 Sprague Dawley-eGFP (SD-eGFP) male rats (Rat Resource &
Research Center, University of Missouri, Columbia, MO). The host rats were irradiated at
10 grays using a Sheperd Mark 1 irradiator. Within a two-hour window immediately postirradiation, each animal received an intravenous tail injection of 500,000 bone marrow cells
suspended in 1 mL of serum-free media. Host rats received equal portions of bone marrow
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aspirate from each donor SD-eGFP rat. The rats were given the antibiotic Enrofloxacin
(trade name Baytril, Bayer Corporation, Germany) for two weeks post-bone marrow
transplant and carefully monitored for 21 days; weight loss of greater than 10% resulted in
the animal being euthanized. At 6 weeks post-bone marrow transplant, 30 chimeric rats were
randomly assigned to experimental groups in the tibial defect study.
2.2. Assessment of rat chimerism
Blood was collected from WT, eGFP, and chimeric rats via the tail vein. Red blood cells
were lysed using Ammonium Chloride Solution (Stem Cell Technologies). The cells were
then stained with CD11b, CD29, CD45, and CD90 (Abcam) antibodies for 1 h at 4 °C. After
1 h, the cells were fixed with 2% PFA solution for 30 min and then re-suspended in 10%
fetal bovine serum (FBS), and stored in 4°C prior to analysis by flow cytometry.

Author Manuscript

2.3. Allograft coating

Author Manuscript

Tibial bone was harvested from 3-month old SD male rats and cut length-wise into 4 mmlong segments for use as allografts in tibial defects. The grafts were stripped of soft tissue,
cleaned with detergent, hydrogen peroxide and ethanol sonication washes and then allowed
to dry [26]. The cleaned allografts were divided into 3 groups: allograft alone, graft with
polymer coating, graft with FTY720-loaded polymer coating. The polymer coating used
50:50 poly(lactic-co-glycolic acid) (PLGA, 69.85 kDa, Lakeshore Bio-materials) dissolved
in methylene chloride at a polymer to solvent ratio of 1:12 (wt:wt). For the drug-loaded
group, FTY720 (343.9 Da, Cayman Chemical) was agitated until dissolved in the polymer
solution at 1:200 drug to polymer ratio (wt:wt). The allograft segments were vortexed in the
FTY720-polymer solution for 10 min. To dry the coating, allografts were stored at 4 °C
overnight and then lyophilized for 24 h to remove the remaining solvent. We have
previously demonstrated that this coating technique enables sustained delivery of FTY720
for at least two weeks in vitro [27] and that the drug remains bioactive [22].
2.4. Rat tibial defect surgery

Author Manuscript

All animal surgeries were performed in accordance with an approved protocol from the
University of Virginia Animal Care and Use Committee. 30 chimeric rats were randomly
assigned to three different experimental groups (n = 10): allograft alone, graft with polymer
coating, graft with FTY720-loaded polymer coating. Rats were anesthetized with isoflurane
gas prior to and during surgery. Prior to surgery, the left hind limb was shaved and sterilized
with betadine and 70% ethanol. A small incision was made longitudinally over the midshaft
of the tibia. Subperiosteal dissection was made after the subcutaneous tissue was dissected
over the anterior aspect of the tibia. Once the bone is exposed, a rotating saw (Dremel
400XPR) was used to make a 4 mm defect distal to the tibial tubercle. The allograft segment
was then inserted into the defect and fixed in position using a 22 gauge needle inserted into
the intramedullary canal from the proximal end of tibia, through the allograft, and into the
distal end of tibia. Ketoprofen was administered subcutaneously at 3 mg/kg doses
immediately post-surgery and every 24 h thereafter for up to 72 h. Rats were given free
access to food and water and monitored for abnormalities and complications. At 2 weeks
post-surgery, 3 rats randomly selected from each experimental group were euthanized by
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injection of 0.5 mL Nembutal into the heart. The left tibial bone was harvested for
subsequent histological analysis.
2.5. X-ray and microCT analysis

Author Manuscript

Radiography was performed at week 0 and week 4 post-surgery. Rats were anesthetized by
intraperitoneal (IP) injection with a cocktail of ketamine HCl (60 mg/kg) and xylazine (5
mg/kg) and then placed on top of an X-ray film inside the X-ray machine (90 s, 30 V
exposure). Yohimbine was given afterward by IP injection to reverse anesthesia. At the end
of the study period (8 weeks post-surgery), rats were euthanized and the tibial bones were
harvested from each rat. The soft tissue surrounding the left tibia and the intermedullary
fixation needle were removed prior to analysis using micro-computed tomography
(microCT) with a VivaCT40 scanner (SCANCO Medical) using the following parameters:
38 μm voxel size, 55 kVp, 145 μA, medium resolution, 40.9 mm diameter field of view, and
200 ms integration time (73 mGy radiation per scan). After microCT scanning, the tibiae
were stored at −20 °C before undergoing mechanical testing. For quantification of microCT
images, a scoring system was developed to assess the extent of integration between host and
allograft bone. For each two-dimensional microCT image, a bridging score between 0 and 4
was assigned. A blinded observer determined whether bridging had occurred in each of four
pre-defined regions of interest. For each region, a binary score of ‘0’ or ‘1’ was assigned,
with ‘1’ indicating the occurrence of bridging within that region. The four values (0 or 1)
were tallied and an overall bridging score was assigned to each animal, with a maximum
score of 4 possible. Subsequently, the minimum distance between the host and donor bone
was quantified in each region of interest using ImageJ software, with all bridges being
assigned a value of ‘0 mm’ to indicate that no space exists between host and donor bone.

Author Manuscript

2.6. Assessment of cell proliferation
MSCs were isolated from WT and chimeric SD rats and seeded in culture plates under
growth media (α-MEM, 15% FBS, 1% Penicillin–Streptomycin (PS), 1% L-Glutamine)
with 0, 0.15 nM or 15 nM FTY720. These concentrations were selected because low dose
FTY720 (below 100 nM) was previously demonstrated to promote osteogenic differentiation
of C2C12 myoblasts [17]. After 10 days of culture, cells were fixed with 10% formalin and
subsequently stained with crystal violet. Subsequent imaging was performed using an
upright microscope at 10× magnification and colony formation was measured by quantifying
the number of pixels above a pre-determined threshold.
2.7. Alizarin red staining

Author Manuscript

MSCs harvested from WT and chimeric SD rats were seeded in culture plates and grown in
growth media (DMEM F12, 10% FBS, 1% PS) for 3 days. The MSCs were then cultured
under osteogenic differentiation media (DMEM-Low Glucose, 10% FBS, 1% PS, 100 nM
Dexamethasone, 10 mM Beta-glycerol phosphate, 2 mM L-Glutamine) and 0.15 nM or 15
nM FTY720. After 10 days, the cells were fixed with 10% formalin and stained with
Alizarin Red S Solution (2% w/v; pH 4.2). The plates were evaluated by light microscopy
and mineralization was measured by quantifying the pixel intensity.
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2.8. Tartrate-resistant acid phosphatase staining
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The RAW264.7 murine macrophage cell line was used to assess the effect of FTY720 on
osteoclastogenesis. Cells were seeded on a coverslip in a culture plate and cultured in
growth media (α-MEM, 10% FBS, 1% PS) with 50 ng/ml murine sRANKL and 0.15 nM or
15 nM of FTY720. Following 5 days of culture, tartrate-resistant acid phosphatase (TRAP)
staining was carried out according to the manufacturer’s instructions (Leukocyte TRAP
Staining Kit 387A, Sigma Aldrich). Stained cells were counter-stained with Hematoxylin
and imaged on an upright microscope.
2.9. Mechanical testing

Author Manuscript

At 8 weeks post-surgery, tibiae were extracted and wrapped in PBS-soaked gauze for
storage at −20 °C until mechanical testing was performed. Immediately prior to testing,
samples were thawed and any residual soft tissue was removed. The distal end of the tibia
was trimmed to center the defect in the sample. The proximal and distal ends of the tibia
were then embedded in end blocks using Wood’s metal (Alfa Aesar) and aligned using a
custom fixture. The sample was loaded into holding brackets mounted on a Bose
ElectroForce System (ELF 3200, Bose Endura TEC) fitted with a 2 Nm loading cell.
Keeping the proximal end fixed, the distal end was rotated at 3° per second until fracture.
Torque and rotation were recorded. Maximum torque was determined by locating the failure
torque.
2.10. Immunohistochemical analysis

Author Manuscript

Animals from each treatment group were euthanized at 8 weeks, and the tibiae were
extracted. Samples were decalcified and embedded in paraffin and 5 μm sections were
prepared. Prior to staining, sections were deparaffinized and antigen retrieval was performed
at 95 °C with 10 mM citrate buffer for 8 min. Sodium borohydride solution (100 mg/mL)
was used to reduce background autofluorescence of the tissue. Samples were permeabilized
with 0.2% Triton X-100 and then blocked using 10% donkey and goat serum to prevent nonspecific antibody binding. Immunofluorescence staining was performed using anti-GFP
(Abcam), anti-Osteocalcin (Abcam), anti-alpha Smooth Muscle Actin (Abcam), isolectin
IB4 (Life Technologies), anti-CCR7 (Abcam), CD206 (Bioss), or CD90 (BioLegend).
Samples were incubated with primary antibody overnight at 4 °C, and secondary antibody
for one hour at room temperature. Slides were mounted in 100 mM glycine and images were
taken on the Zeiss LSM 700 confocal microscope using Zen software (Zeiss). Quantification
of immunohistochemistry was performed by counting the number of cells positive for the
specified markers by identifying a threshold based on secondary only controls. For
identification of newly formed bone, sections were stained with hematoxylin and eosin and
then imaged for autofluorescence using an upright microscope.

Author Manuscript

3. Results
3.1. Development and characterization of eGFP rat chimeras
To gain insight into how circulating cell populations contribute to allograft incorporation in
a critical sized rat tibial defect model, we generated chimeric rats expressing eGFP in the
bone marrow compartment. eGFP−/− SD rats were lethally irradiated and transplanted with
Biomaterials. Author manuscript; available in PMC 2016 September 01.
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bone marrow derived from eGFP+/− litter mates, resulting in 100% survival of all transplant
recipients (Fig. 1A). Flow cytometry analysis revealed that 75% of circulating white blood
cells were GFP+ cells (Fig. 1B). Additionally, chimeric rats demonstrated reconstitution of
CD11b+, CD29+, CD45+, and CD90+ lineages in blood at 4 weeks post-transplantation (Fig.
1C), signifying successful and stable transplantation with GFP+ bone marrow.

Author Manuscript

Bone marrow stromal cells from chimeric rats remain primarily uncharacterized in their
proliferative and differentiation capacities. We compared colony formation and osteogenic
differentiation of MSCs derived from WT and chimeric rats. Chimeric MSCs formed larger
colonies that covered 5-fold more area and demonstrated a 5-fold increase in average size
compared to WT MSCs (Fig. 1D), without impacting the overall colony number. MSCs
from chimeric rats more highly stained with Alizarin Red, indicating that chimeric MSCs
generate more mineralized matrix in vitro (Fig. 1E). This likely results either from an overall
increase in the number of cells capable of mineralization or an increase in the average output
per cell. These findings highlight an important difference in the behavior of MSCs derived
from rats undergoing hematopoietic reconstitution with cells derived from eGFP+/− rats that
should be considered when designing experiments that investigate the role of bone marrows
cells in chimeric rats.
3.2. Bone growth and allograft incorporation in a long bone defect model
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Critical sized segmental defects (4 mm) were generated in the tibiae of chimeric rats 6
weeks after lethal irradiation and bone marrow transplantation. Allograft incorporation was
monitored at weeks 0 and 4 by X-ray and week 8 by ex vivo microCT scans. X-ray imaging
indicates that animals treated with FTY720-coated allografts show better graft integration
and callus formation as early as 4 weeks (Fig. 2A). MicroCT images taken at week 8
indicate that this leads to new mineralized bone formation and better healing in animals
treated with grafts coated with FTY720 (Fig. 2B). In particular, the interface between donor
and host bone is less distinct in animals receiving FTY720, indicating improved allograft
incorporation. We scored the extent of bridging that occurred between allograft and host
bone in two-dimensional microCT renderings and found that FTY720 significantly increases
bridging relative to both uncoated and PLGA-coated grafts (Fig. 2C). Additionally, FTY720
reduces the overall distance between host and donor bone compared to uncoated controls
(Fig. 2D). H&E staining of tibiae longitudinally sectioned through the defect site also show
more bone formation and better graft integration in animals treated with FTY720-coated
allografts compared to controls (Supplemental Fig. 1).

Author Manuscript

In the case of load-bearing bone repair, newly-deposited bone must be able to support the
mechanical load exerted by the rest of the body. We used torsional testing to measure the
magnitude of forces sustained by newly-healed bone. While we experienced significant
sample variability in mechanical testing, inspection of the force–displacement curves shows
that FTY720-treated grafts exhibited mechanical properties more similar to uninjured
contralateral bones (Fig. 2E). Across all tested samples, FTY720 best restores the strength of
native bone, as the torque at failure is most similar to contralateral controls (Supplemental
Fig. 2). No significant differences in stiffness between all groups were observed.
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3.3. S1P signals regulate osteogenic processes
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Given that polymer coatings releasing FTY720 promote allograft incorporation and
mineralization, we assessed the presence of osteocalcin-positive (OC+) cells at the interface
between allograft bone and host tissue. FTY720-coated allografts have a higher frequency of
OC+ cells in the surrounding tissue than uncoated or PLGA-coated allografts as detected by
immunohistochemistry (Fig. 3A, B). Additionally, in animals receiving FTY720, OC+ cells
infiltrated void areas within the graft and closely associated with donor bone, enabling bone
deposition at the graft surface. Fluorescence measurements of histological sections, in which
new bone autofluoresces more brightly, indicate a greater amount of newly-formed bone in
animals receiving FTY720 allografts (Supplemental Fig. 1). New bone formation is the
cumulative result of a delicate balance between osteoblast deposition of mineralized matrix
and osteoclast resorption of damaged bone. Consequently, we investigated the effect of S1P
receptor signaling on both osteoblastic and osteoclastic behaviors in vitro. Low dose
FTY720 appears to minimally impact colony formation of MSCs, as total colony coverage
only slightly increased (Fig. 3C) and colony number was not impacted by the presence of
0.15 nM or 15 nM FTY720. The osteogenic capacity of MSCs appears to be enhanced by
S1P signals, as the intensity of Alizarin Red staining increased in the presence of FTY720
and this was associated with a modest increase in the total percentage of mineralized regions
(Fig. 3C and D). To study the effect of FTY720 on osteoclastogenesis, we treated
RAW264.7 macrophages with RANKL and stained for TRAP. Low (0.15 nM) and high (15
nM) dose FTY720 increased osteoclastic differentiation, with the lower dose having the
greatest effect (Fig. 3E). Taken together, these results indicate that FTY720 released from
degradable allograft coatings likely alters the fate of osteoblastic and osteoclastic precursors
in the peri-implant tissue.

Author Manuscript

3.4. FTY720 promotes vascular maturation in healing bone
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We have previously demonstrated that local delivery of FTY720 increases the formation of
vascular networks in remodeling bone after injury [19,22]. Here, the dynamics of FTY720’s
effects on vascular ingrowth into transplanted allografts were assessed by visualizing lectin+
microvessels and mature SMA+ blood vessel formation after bone injury. At 2 weeks postinjury, SMA+ cells were primarily unassociated into vascular structures and were prominent
in the tissue surrounding the graft (Fig. 4A). By week 8, the interfacial tissue appeared much
more highly vascularized, with the appearance of lectin+ microvessels and large smooth
muscle-coated SMA+ vessels having a diameter greater than 100 μm (Fig. 4B and C).
Groups receiving FTY720 appear to have more lectin+ and SMA+ blood vessels
surrounding the allograft and more SMA+ cells infiltrating donor bone at week 8 post-injury
(Fig. 4B and C). Interestingly, these group differences were not observed in week 2
histological sections, indicating that FTY720 likely affects the maturation of nascent
vasculature formed during early wound healing processes. FTY720 had a more robust effect
on SMA+ blood vessels than lectin+ vessels, further supporting the hypothesis that FTY720
promotes vascular maturation. Moreover, FTY720’s effect on vascularization in and around
implanted allografts likely contributes to improved allograft incorporation and bone
regeneration.
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3.5. Fate of bone marrow-derived cells during bone regeneration

Author Manuscript
Author Manuscript
Author Manuscript

The precise role of circulating and resident cell populations, including inflammatory cells
and mesenchymal progenitors, to bone healing remains unclear. While it is apparent that
infiltrating inflammatory cells likely participate in repair processes, the relative
contributions by blood and tissue compartments has not been characterized. To assess the
frequency of bone marrow-derived cells that becomes M1-like or M2-like macrophages,
histological sections stained with anti-GFP antibody were counterstained for CCR7 (for M1like macrophages) or CD206 (for M2-like macrophages) expression (Fig. 5A). We
quantified the ratio of GFP+CD206+ to GFP+CCR7+ cells to investigate whether FTY720
alters the fate of bone marrow-derived inflammatory cells. At 2 weeks post-injury, we
measured a 30% increase in the ratio of GFP+CD206+ to GFP+CCR7+ cells, suggesting
that FTY720 changes the phenotype of recruited macrophages (Fig. 5B). Additionally, in
animals not receiving FTY720, CD206+ cells appear to be excluded from the tissue space
that is immediately adjacent to implanted grafts, likely reducing their ability to guide repair
processes and graft integration. GFP+ cells represent cells derived from transplanted bone
marrow and thus correlate to circulation-derived cells or tissue-resident cells that were
replenished by circulating cells during the 6-week pre-surgery period of hematopoietic
reconstitution. Consequently, GFP-negative cells signify populations that were protected
from irradiation, likely consisting of embryonically-derived tissue resident immune cells,
stromal and parenchymal cells, and a small frequency (20–30%) of non-GFP+ circulating
cells (Fig. 1B). GFP+ cells infiltrated the interfacial tissue space surrounding allografts, with
a subset of cells also expressing CCR7 or CD206 (Fig. 5A, white arrows). Quantification
across all animal groups indicates that CCR7+ M1-like macrophages encompass a larger
frequency of GFP+ cells (30%) than CD206+ M2-like macrophages (20%), indicating that
at 2 weeks post-injury, bone marrow-derived cells have a greater probability of adopting an
inflammatory phenotype (Fig. 5C). Interestingly, the GFP+ population makes up an equal
proportion of CCR7+ and CD206+ cells (Fig. 5D). These results indicate that both a
circulating and a tissue resident, irradiation-resistant population contribute to the
inflammatory cell profile during early stage bone regeneration and FTY720 may promote
tissue repair by shifting the phenotype of recruited macrophages to a pro-regenerative M2like profile.
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Monocyte-derived macrophages represent a population of blood- and bone marrow-derived
progenitor cells that play critical roles in dictating the capacity of an injury to heal. In the
context of bone repair, these cells participate in crosstalk with osteoblasts and mesenchymal
progenitors, as well as vascular endothelial cells [8]. Consequently, we assessed whether
progenitor cells surrounding allograft implants express GFP. In all treatment groups, CD90+
cells that co-stained for GFP were observed in sections taken at week 2 post-injury,
indicating that a subset of these progenitor cells originates from bone marrow (Fig. 6D).
Moreover, we were interested in whether more mature osteoblastic cells were derived from
the bone marrow compartment. Interestingly, we observed cells that stained positive for both
OC and GFP, indicating that a fraction of OC+ osteoblastic cells are derived from the bone
marrow compartment 8 weeks after injury (Fig. 6A). FTY720 does not appear to affect the
absolute number of GFP+OC+ bone marrow-derived osteoblatic cells in the tissue
surrounding allograft (Fig. 6B); however, the proximity of these cells to the graft and
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intensity of osteocalcin staining is enhanced in FTY720 animals (Fig. 6A). Quantification of
histological sections from all groups indicated that as many as 25% of OC+ cells were
derived from bone marrow (Fig. 6C). While this is much lower than the contribution of WT
cells to the OC+ population in healing bone, this data indicates that there is likely a
significant role for osteogenic progenitor cells derived from bone marrow in healing bone.

4. Discussion

Author Manuscript

The precise role of bone marrow- and circulation-derived progenitor cells in bone healing
remains poorly understood, and thus the design of strategies that exploit the relative
contributions of these cells has been limited. Peripheral blood mononuclear cells encompass
a heterogeneous cell population containing many different cell types that may participate in
bone healing, including monocytes/macrophages, neutrophils, endothelial progenitor cells,
and osteogenic progenitor cells. Elucidation of the respective roles for various tissue
compartments in bone repair is critical for designing novel therapeutics that harness these
cell populations to promote healing. The current work systematically examines the
contributions of GFP+ cells that are derived from reconstituted bone marrow during healing
of critical-sized tibial defects in chimeric rats and examines whether lipid-based therapies
can improve post-trauma functional recovery of damaged bone by directing progenitor cell
fate.
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Macrophages represent a multi-faced population of cells that differ in recruitment kinetics
and function in a wide range of injury contexts. These cells are required for efficient bone
repair, as systemic depletion of macrophages with clodronate liposomes significantly
impairs tibial defect healing [28]. Macrophages exhibit a wide range of diverse phenotypes
that have been primarily categorized into “classically activated” M1 macrophages, which
possess pro-inflammatory, phagocytic, and proteolytic functions essential for removal of
damaged tissues, and “alternatively activated” M2 macrophages, which are antiinflammatory and participate in tissue regeneration, angiogenesis, and matrix synthesis [29].
In vivo, injury-responsive macrophages are extremely heterogeneous, existing along a
spectrum of phenotypes, with the M1 and M2 phenotypes representing opposite extremes.
An additional level of complexity exists due to the fact that macrophages present at
inflammatory sites may be derived from either circulation or tissue resident macrophage
pools that are embryonically-derived and self-renewing during homeostasis [30].
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Our data indicates that bone marrow-derived GFP+ cells are more likely to become CCR7+
than CD206+ at 2 weeks post-injury (Fig. 5C). The kinetics of specific macrophage
phenotypes is not well-characterized, particularly in the context of bone repair. However, the
current work indicates that specification down an M1-like lineage is more prominent during
early bone repair, suggesting that the characteristic pro-inflammatory phase may be
extended beyond a couple of days to several weeks during bone healing. Interestingly, GFP+
cells contribute equal proportions to both CCR7+ and CD206+ populations (Fig. 5D), likely
indicating that the injury microenvironment is the primary determinant of macrophage
phenotype, as there is no difference in the fate of either recruited or tissue resident
populations. We have previously reported that local delivery of FTY720 skews the
inflammatory profile to generate a pro-regenerative injury niche, both in soft tissue and
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craniofacial bone [18,19]. In particular, FTY720 increases the frequency of antiinflammatory M2 macrophages both at early (3 days) and later (3 weeks) time points, which
facilitates neo-vascularization and tissue repair. In the current work, FTY720 increased the
ratio of GFP+ M2:M1 macrophages at 2 weeks post-injury, which likely leads to
improvements in vascularization and allograft bridging observed by 8 weeks (Fig. 5B).
FTY720 more robustly induced the formation of SMA+ mature blood vessels than lectin+
vessels around implanted allografts (Fig. 4B and C), indicating that FTY720 likely promotes
vascular maturation, which could be initiated by pro-arteriogenic macrophages.
Additionally, myeloid cells are a key player in coupling osteogenesis to angiogenesis [8] and
the precise ratio of M2:M1 macrophages likely dictates the ability of injured tissue to
regenerate [31,32].
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While the occurrence of myeloid cell infiltration from the blood during bone repair is welldocumented, the existence and role of circulating osteogenic progenitor cells is less
understood. Peripheral blood cells that express osteogenic markers such as osteocalcin or
alkaline phosphatase have been detected both in murine and human samples [33,34]. In
studies using parabiotic mice in which a WT and a chimeric mouse containing GFP-labeled
bone marrow were conjoined, BMP-2-laden pellets were subcutaneously implanted. OC+
GFP+ cells were found at surrounding ectopic bone in the WT mouse [35] and in similar
parabiotic studies using a fracture model, indicating the existence of circulation-derived
GFP+ bone-forming cells. Additionally, administration of compounds that increase the
frequency of osteogenic progenitor cells in circulation such as the CXCR4 inhibitor
AMD3100, increases ectopic bone formation [36] and improves fracture healing [37]. These
results indicate that bone marrowand circulation likely contribute to bone repair, but the
precise contribution may be context-dependent, where both the size and location of injury
are important. In the present work, we observed that the bone marrow compartment
significantly contributes to the pool of tissue OC+ cells, with as many as 25% being GFP+
at week 8 post-injury (Fig. 6C). The source of these cells is not clear and could derive from
circulating osteogenic cells or contiguous marrow that migrates in response to injuryinduced chemotactic cues [6]. It is likely that at least a population of these cells were derived
from a pool of GFP+CD90+ progenitor cells that appeared at the injury site at week 2 postsurgery (Fig. 6D). The reported mechanisms of OC+ cell infiltration appear to be conserved
across multiple types of bone injury, as fracture healing also induces bone marrow-derived
OC+ cell infiltration [38]. FTY720 localizes OC+ cells to the graft surface (Fig. 3A), which
may be through enhanced recruitment of progenitor cells, as we have previously reported
that local FTY720 increases tissue levels of chemokines such as SDF-1 and RANTES [18].
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Healing damaged bone is a function of both the amount of osteogenic cells active within the
defect area, as well as the osteogenic capacity of each individual cell. While allografts
provide a scaffold for cell and tissue ingrowth into the defect area, non-union remains a
major concern, in part due to insufficient infiltration of osteogenic cells. Consequently,
small molecule-based approaches for increasing the recruitment and differentiation of boneforming cells represents a viable and translational approach for improving allograft
functionality [39]. In this study, we show that in addition to an increase in the frequency of
OC+ cells at the allograft integration site, the osteogenic capacity of MSCs is also elevated
after FTY720 treatment (Fig. 3B). The osteogenic effects of FTY720 enabled newly formed
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bone to sustain higher torsional forces and exhibited a deformation pattern similar to that
sustained by native, unbroken bone (Fig. 2E).
The current work advances our understanding of the role that bone marrow-derived
progenitor cells play in bone regeneration and allograft incorporation. While cell infiltration
from blood and bone marrow are likely context- and time-dependent, a significant
contribution to both osteogenic and inflammatory cell populations from irradiation-sensitive
hematopoietic tissues was observed. The development of novel strategies to improve clinical
bone reconstruction and regeneration will likely depend on an understanding of endogenous
mechanisms of cell recruitment and their in situ roles in repair. Therapies derived from
engineering progenitor cell migration within the injury microenvironment represent a
promising and powerful approach for bone repair.
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5. Conclusions
Development of tissues that fully interface with damaged host tissue remains a significant
challenge for the field of tissue engineering. Allografts, which recapitulate some of the
structure and function of native bone, would likely have a better clinical outcome if coupled
to strategies that specifically guide endogenous cell recruitment. The current work
demonstrates that bone marrow-derived progenitor cells infiltrate rat critical sized bone
defects and significantly contribute to inflammatory and bone-forming cell populations.
Bioactive allograft coatings containing FTY720 improve graft vascularization, bone
formation, and integration with host tissue, likely through local immune modulation that
improves angiogenic–osteogenic coupling. Future strategies for engineering bone
regeneration will likely rely on an understanding of endogenous mechanisms of repair to
identify therapeutic targets and maximizing cellular contributions.
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Rat bone marrow chimeras as a model for studying bone regeneration. (A) Sprague–Dawley
rat bone marrow chimeras were generated by transplanting eGFP+ bone marrow into
lethally irradiated eGFP−/− rats. Tibial defects were created 6 weeks post-transplantation.
(B) Flow cytometry analysis of eGFP expression in blood 4 weeks post-bone marrow
transplantation demonstrated stable reconstitution of the hematopoietic system with GFP+
cells, n = 3–4. (C) GFP+ cells display multi-lineage differentiation as assessed by flow
cytometry analysis of blood taken 4 weeks post-transplantation, n = 3. (D) Bone marrow
from chimeras after 7 days of culture as observed with crystal violet staining (left) and
quantification of colony coverage (right), n = 6. (E) Bone marrow from eGFP chimeras after
7 days of culture in osteogenic media as observed with Alizarin red staining (left) and
quantification of mineralized area (right), n = 3. Scale bar, 100 μm; *p < 0.05. (For
interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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Fig. 2.
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FTY720-coated allografts promote bone formation and graft incorporation. (A)
Representative X-rays of tibiae indicate the FTY720 improves integration between host and
donor bone by week 4 post-injury. (B) Representative microCT reconstructed images taken
at 8 weeks post-injury indicate that FTY720 increases bone deposition around implanted
allgorafts (top row: 3D images, bottom row: 2D cross-sectional images). (C) FTY720
increases the bridge score assessed in 2D microCT images compared to uncoated and
PLGA-coated allograft controls, n = 4–5. (D) FTY720 decreases the distance between host
and donor bone compared to uncoated allografts, n = 4–5. (E) Representative torque plots
from torsional mechanical testing of tibiae explanted 8 weeks post-injury indicate that
FTY720 allografts better recapitulate the mechanical properties of uninjured contralateral
control bone, n = 3–4. Scale bars, 500 mm; *p < 0.05.
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Fig. 3.
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FTY720 promotes osteogenesis and osteoclastogenesis. (A) Histological sections from tibiae
explanted at week 8 post-injury and immunostained with anti-osteocalcin (OC) and DAPI
demonstrate that FTY720 increases the frequency of OC+ cells and their proximity to the
graft, n = 2–3. Scale bars, 100 μm; white arrows, OC+ cells; dotted line, graft edge. (B)
Quantification of histological sections stained with OC, n = 2–3. (C) Bone marrow from
wild type animals cultured for 7 days in the presence of low (0.15 nM) and high (15 nM)
dose FTY720 and stained with crystal violet (top) or Alizarin red (bottom). (D)
Quantification of colony cell coverage (left) or amount of mineralization (right) shows that
FTY720 minimally impacts colony size, but increases mineralization of MSCs, n = 3–6. (E)
FTY720 promotes osteoclastogenesis as assessed by TRAP staining of RAW264.7 cells
cultured for 5 days in RANKL and low or high dose FTY720. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this
article.)
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Fig. 4.

FTY720 increases the number of α-SMA+ blood vessels surrounding allografts. (A)
Histological sections from tibiae explanted and immunostained with anti-α smooth muscle
actin (SMA) and DAPI show that few mature blood vessels are present around allografts in
all groups at 2 weeks post-injury. (B) FTY720 promotes formation of lectin+ microvessels
by 8 weeks post-injury, n = 2–3. (C) FTY720 promotes formation of mature smooth musclecoated blood vessels by 8 weeks post-injury, n = 2–3. Scale bars, 100 μm; dotted line, graft
edge. *p < 0.05.
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Fig. 5.
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The phenotype of bone marrow-derived macrophages is altered by FTY720. (A)
Histological sections from tibiae explanted at week 2 post-injury and stained with anti-GFP,
DAPI, and CCR7 (top row) or CD206 (bottom row). Scale bars, 50 μm; white arrows, GFP
+CCR7+ or GFP+CD206+ cells; dotted line, graft edge. (B) FTY720 increases the ratio of
CD206+GFP+ to CCR7+GFP+ cells at 2 weeks post-injury, n = 2–3. (C) Quantification of
the percentage of CCR7+ and CD206+ cells within the total GFP+ cell population
demonstrates that across all groups, GFP+ bone marrow-derived cells are more likely to
become CCR7+ than CD206+ at 2 weeks post-injury, n = 7–8. (D) Quantification of the
percentage of total CCR7+ and CD206+ cells that also express GFP demonstrates that
across all groups, the bone marrow contributes equal proportions to both CCR7+ and
CD206+ cells at 2 weeks post-injury, n = 7–8. *p < 0.05.
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Fig. 6.

Bone marrow contributes to mature bone-forming cells and osteogenic progenitor cells. (A)
Histological sections from tibiae explanted at week 8 post-injury and stained with anti-GFP,
OC, and DAPI. White arrows, GFP+OC+ cells; dotted line, graft edge. (B) FTY720 does not
impact the number of GFP+OC+ cells in histological sections imaged around the graft, n =
2–3. (C) Across all groups, GFP+ bone marrow-derived cells contribute significantly less
(about 25%) than unlabeled wild type (WT) cells (about 75%) to OC+ populations detected
8 weeks post-injury, n = 7. (D) Histological sections from tibiae explanted at week 2 postinjury and stained with anti-GFP, anti-CD90, and DAPI. White arrows, GFP+CD90+ cells.
Scale bars, 50 μm; *p < 0.05.
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